Press Releases
  Date Title View
Mar 12, 2017
Data Confirm Use of Archival Tumor Tissue to Determine Patient Selection in FORWARD I WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that data ...
PDF
Mar 1, 2017
Nine presentations featuring the Company's leadership in ADCs WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that nine abstracts highlighting the breadt...
PDF
Feb 17, 2017
First Patient Enrolled in Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine Continued Momentum in 2017 with Data Expected from Pipeline Programs Conference Call to be Held at 8:00am ET Today WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc...
PDF
Feb 2, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: ...
PDF
Jan 26, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been dosed in FORWARD I, the Company's Phase 3 clinical trial evaluating mirvetuximab soravtansine a...
PDF
Jan 25, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 17, 2017, to discuss ImmunoGen's financial res...
PDF
Jan 23, 2017
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Sandra Poole, Executive Vice President, Technical Operations and Commercial Development, will leave the Company at the end...
PDF
Dec 28, 2016
Positive Results Form Basis for FORWARD I Phase 3 Registration Trial WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the Phase ...
PDF
Dec 28, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 35th Annual J. P. Morgan Healthcare Conference in San Francisco. Th...
PDF
Dec 5, 2016
Data Demonstrate Activity in Acute Myeloid Leukemia Models While Sparing Normal Bone Marrow WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that precl...
PDF
Nov 11, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced new preclinical data that demonstrate the potential for enhanced activity when combining mirvetuximab soravtansine with immune ...
PDF
Nov 3, 2016
Includes Oral Presentation on CD123-Targeting ADC IMGN632 WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new preclinical data on the Company's nove...
PDF
Oct 28, 2016
Phase 3 FORWARD I Trial of Mirvetuximab Soravtansine On Track to Begin before Year End FORWARD II Trial Assessing Mirvetuximab Soravtansine Combinations with Avastin®, Carboplatin, Doxil®, and Keytruda® Ongoing Strategic Review Completed to Strengthen Underl...
PDF
Oct 14, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 28, 2016, to discuss ImmunoGen's financial resu...
PDF
Sep 29, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the completion of a strategic review of its operations. As a result of this initiative, the Company will reduce its workforce b...
PDF
Aug 9, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Charles Morris, MBChB, MRCP, Executive Vice President and Chief Development Officer, is leaving the Company effec...
PDF
Aug 5, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming investor conferences will be webcast: ...
PDF
Aug 4, 2016
− Conference call at 8:00 am ET today - Following positive meeting with FDA, Phase 3 FORWARD I study of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer on track to begin before year end. Mirvetuximab soravtansine plus Avastin...
PDF
Jul 21, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, August 4, 2016, to discuss ImmunoGen's financial results for the...
PDF
Jun 15, 2016
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of $100 million aggregate principal amount of its 4.50% convertible senior notes due 2021 (the "Notes") in a private placement. The Notes will be offered by the initial purchasers only to qualified institutional buyers ...
PDF
1
... NextLast

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue